Article Text

PDF

Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.
  1. S A Factor,
  2. J R Sanchez-Ramos,
  3. W J Weiner
  1. University of Miami School of Medicine, Department of Neurology, Florida 33101.

    Abstract

    Sixty-three patients with Parkinson's disease who failed bromocriptine therapy for various reasons were treated in an open-label trial of pergolide. The data were evaluated in a retrospective manner. Forty-six percent had a good response and tolerated the pergolide. A comparison of the outcomes regarding response and toxicity revealed that bromocriptine and pergolide act differently in individual patients. A trial of pergolide in Parkinsonian patients failing bromocriptine therapy may be therapeutically useful.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.